secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056866
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q1 2024 net loss $8.6M, cash $13.0M; first patient dosed in INB-400 Phase 2
--------------------------------------------------------------------------------

- Q1 net loss $8.6M ($0.20/sh) vs $7.5M ($0.30/sh) in Q1 2023; R&D $4.9M, G&A $3.7M.
- Cash $13.0M at March 31, 2024, down from $21.3M at December 31, 2023.
- First patient dosed in Phase 2 autologous arm of INB-400 for newly diagnosed GBM.
- Potential IND submission for INB-100 Phase 2 registrational trial in 2024 in AML/MDS.
- Preclinical nsCAR data at AACR 2024 targeting CD33/CD123 for AML while sparing healthy cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/0000950170-24-056866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/inab-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer